Anavex Life Sciences Corp (AVXL)

[TTTav66]

Notable recent hire; Michael Kornhauser has joined the Anavex team as "Australian Clinical & Scientific Lead". From LinkedIn, it looks like as of March he left his position, “Associate Director, National Clinical Trials”, at HammondCare. This move comes after having worked with blarcamesine across trials at Alfred Health and HammondCare since 2014. He comments on this work in a post after the initial PDD results:

Great news in the fight against dementia!

My team & I have been working with ANAVEX’s lead compound (blarcamesine) since 2014. We have seen this compound time and again improve the lives people with Alzheimer’s Disease. Now, in a phase 2 placebo controlled RCT, it has shown potential in the fight against Parkinson’s Dementia too.

I am so proud to be part of only two clinical trial sites in Australia in this effort.

This successful trial is another example of how the Australia research ecosystem is welcoming, collaborative and accommodating for smaller biotech companies.

The fight against these dreaded diseases is moving forward – keep the good news coming!

He’s interviewed in this story from last year on the 2b/3 AD trial:

A drug which appears to slow Alzheimer's is being offered to more Victorians as part of a clinical trial. @EmilyRice28 #9News pic.twitter.com/IqKUXKzlhA

— 9News Melbourne (@9NewsMelb) January 28, 2020

Encouraging, imo, to see both him make the decision to join the team at this juncture, and for Anavex to be adding this role.